Protective efficacy of influenza group 2 hemagglutinin stem-fragment immunogen vaccines

npj Vaccines

Volumn 2, Issue 1, 2017, Pages

  Sutton, Troy C ^a   Chakraborty, Saborni ^b   Mallajosyula, Vamsee V A ^b   Lamirande, Elaine W ^a   Ganti, Ketaki ^a   Bock, Kevin W ^a   Moore, Ian N ^a   Varadarajan, Raghavan ^b   Subbarao, Kanta ^a,c  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b INDIAN INSTITUTE OF SCIENCE   (India)

^c PETER DOHERTY INSTITUTE FOR INFECTION AND IMMUNITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85042233316     PISSN: None     EISSN: 20590105     Source Type: Journal    
DOI: 10.1038/s41541-017-0036-2     Document Type: Article

References (44)

1. WHO. 2016 Influenza (Seasonal) fact sheet http://www.who.int/mediacentre/factsheets/fs211/en/ (2016).
2. Taubenberger, J. K. & Morens, D. M. 1918 Influenza: the mother of all pandemics. Emerg. Infect. Dis. 12, 15-22 (2006).
3. Luke, C. J., Lakdawala, S. S. & Subbarao, E. K. in Vaccines, Vol. 6 (eds S. A. Plotkin, W. A. Orenstein, & P. A. Offit) Ch. 18, 294-311 (Elsevier, Philadelphia, 2013).
4. Wu, Y., Wu, Y., Tefsen, B., Shi, Y. & Gao, G. F. Bat-derived influenza-like viruses H17N10 and H18N11. Trends Microbiol. 22, 183-191 (2014).
5. Skehel, J. J. & Wiley, D. C. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu. Rev. Biochem. 69, 531-569 (2000).
6. Corti, D. & Lanzavecchia, A. Broadly neutralizing antiviral antibodies. Annu. Rev. Immunol. 31, 705-742 (2013).
7. Corti, D. et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J. Clin. Invest. 120, 1663-1673 (2010).
8. Dreyfus, C. et al. Highly conserved protective epitopes on influenza B viruses. Science 337, 1343-1348 (2012).
9. Miller, M. S. et al. Neutralizing antibodies against previously encountered influenza virus strains increase over time: a longitudinal analysis. Sci. Transl. Med. 5, 198ra107 (2013).
10. Throsby, M. et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+memory B cells. PLoS. One. 3, e3942 (2008).
11. Van, T. D., Tran, N., Le, L. & Eisenhaber, F. A Perspective on rational designs of a hemagglutinin based universal influenza vaccine. Curr. Pharm. Des. 3547-3554 (2016).
12. Krammer, F., Pica, N., Hai, R., Margine, I. & Palese, P. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J. Virol. 87, 6542-6550 (2013).
13. Steel, J. et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio. https://doi.org/10.1128/mBio.00018-10 (2010).
14. Wei, C. J. et al. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 329, 1060-1064 (2010).
15. Margine, I. et al. Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses. J. Virol. 87, 10435-10446 (2013).
16. Bommakanti, G. et al. Design of Escherichia coli-expressed stalk domain immunogens of H1N1 hemagglutinin that protect mice from lethal challenge. J. Virol. 86, 13434-13444 (2012).
17. Impagliazzo, A. et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science 349, 1301-1306 (2015).
18. Mallajosyula, V. V. et al. Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection. Proc. Natl. Acad. Sci. USA 111, E2514-E2523 (2014).
19. Mallajosyula, V. V. et al. Hemagglutinin sequence conservation guided stem immunogen design from influenza A H3 subtype. Front. Immunol. 6, 329 (2015).
20. Valkenburg, S. A. et al. Stalking influenza by vaccination with pre-fusion headless HA mini-stem. Sci. Rep. 6, 22666 (2016).
21. Yassine, H. M. et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat. Med. 21, 1065-1070 (2015).
22. Krammer, F., Pica, N., Hai, R., Tan, G. S. & Palese, P. Hemagglutinin stalk-reactive antibodies are boosted following sequential infection with seasonal and pandemic H1N1 influenza virus in mice. J. Virol. 86, 10302-10307 (2012).
23. Corti, D. et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333, 850-856 (2011).
24. Julien, J. P., Lee, P. S. & Wilson, I. A. Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA. Immunol. Rev. 250, 180-198 (2012).
25. Bommakanti, G. et al. Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc. Natl. Acad. Sci. USA 107, 13701-13706 (2010).
26. Krammer, F. & Palese, P. Advances in the development of influenza virus vaccines. Nat. Rev. Drug Discov. 14, 167-182 (2015).
27. Lu, Y., Welsh, J. P. & Swartz, J. R. Production and stabilization of the trimeric influenza hemagglutinin stem domain for potentially broadly protective influenza vaccines. Proc. Natl. Acad. Sci. USA 111, 125-130 (2014).
28. Ekiert, D. C. et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333, 843-850 (2011).
29. Friesen, R. H. et al. A common solution to group 2 influenza virus neutralization. Proc. Natl. Acad. Sci. USA 111, 445-450 (2014).
30. Jia, B. & Jeon, C. O. High-throughput recombinant protein expression in Escherichia coli: current status and future perspectives. Open Biol https://doi.org/10.1098/rsob.160196 (2016).
31. Brandenburg, B. et al. Mechanisms of hemagglutinin targeted influenza virus neutralization. PLoS One 8, e80034 (2013).
32. DiLillo, D. J., Palese, P., Wilson, P. C. & Ravetch, J. V. Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. J. Clin. Invest. 126, 605-610 (2016).
33. DiLillo, D. J., Tan, G. S., Palese, P. & Ravetch, J. V. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nat. Med. 20, 143-151 (2014).
34. Krammer, F. et al. Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets. J. Virol. 88, 3432-3442 (2014).
35. Nachbagauer, R. et al. Hemagglutinin stalk immunity reduces influenza virus replication and transmission in ferrets. J. Virol. 90, 3268-3273 (2015).
36. Chen, G. L. et al. Evaluation of three live attenuated H2 pandemic influenza vaccine candidates in mice and ferrets. J. Virol. 88, 2867-2876 (2014).
37. Houser, K. V., Pearce, M. B., Katz, J. M. & Tumpey, T. M. Impact of prior seasonal H3N2 influenza vaccination or infection on protection and transmission of emerging variants of influenza A(H3N2)v virus in ferrets. J. Virol. 87, 13480-13489 (2013).
38. Pushko, P. et al. Recombinant H7 hemagglutinin forms subviral particles that protect mice and ferrets from challenge with H7N9 influenza virus. Vaccine 33, 4975-4982 (2015).
39. Wong, S. S. et al. A single dose of whole inactivated H7N9 influenza vaccine confers protection from severe disease but not infection in ferrets. Vaccine 32, 4571-4577 (2014).
40. Nachbagauer, R. et al. Defining the antibody cross-reactome directed against the influenza virus surface glycoproteins. Nat. Immunol. 18, 464-473 (2017).
41. Sharma, D. et al. Protein minimization of the gp120 binding region of human CD4. Biochemistry 44, 16192-16202 (2005).
42. Guthe, S. et al. Very fast folding and association of a trimerization domain from bacteriophage T4 fibritin. J. Mol. Biol. 337, 905-915 (2004).
43. Chen, K. S. & Quinnan, G. V. Jr. Induction, persistence and strain specificity of haemagglutinin-specific secretory antibodies in lungs of mice after intragastric administration of inactivated influenza virus vaccines. J. Gen. Virol. 69, 2779-2784 (1988).
44. Baz, M. et al. A single dose of an avian H3N8 influenza virus vaccine is highly immunogenic and efficacious against a recently emerged seal influenza virus in mice and ferrets. J. Virol. 89, 6907-6917 (2015).